KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients.

S Gupta, M A Climent Duran, S S Sridhar, T Powles, J Bellmunt, S H Park, H Gurney, N Tsuchiya, D P Petrylak, Y Tomita, A di Pietro, J Manitz, K Tyroller, J Hoffman, N Jacob, P Grivas

ESMO Open 10(4) 104506

PMID40107155
PMCIDPMC11964637
DOI10.1016/j.esmoop.2025.104506
发表日期2025-03-19
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

BACKGROUND: In the JAVELIN Bladder 100 phase III trial, avelumab first-line (1L) maintenance plus best supportive care (BSC) significantly prolonged overall survival (OS) versus BSC alone in patients with locally advanced or metastatic urothelial carcinoma (la/mUC) without progression following platinum-based chemotherapy. Older age (≥65 years) is a known risk factor for bladder cancer with a median age at diagnosis of 73.0 years. We report exploratory analyses in subgroups based on older age (≥65 years). MATERIALS AND METHODS: Eligible patients with la/mUC without progression after 1L platinum-based chemotherapy were randomized to receive avelumab plus BSC (n = 350) or BSC alone (n = 350). This exploratory analysis included subgroups aged ≥65 years, ≥65-<75 years, ≥75 years, and the subset aged ≥80 years. OS (primary endpoint) and progression-free survival (PFS) from randomization were analyzed using the Kaplan-Meier method. RESULTS: Of 700 patients, 464 (66.3%) were aged ≥65 years. Median OS with avelumab plus BSC versus BSC alone was 26.1 versus 15.5 months (hazard ratio 0.70, 95% confidence interval 0.56-0.89) in all patients aged ≥65 years and 28.7 versus 17.1, 24.0 versus 13.5, and 24.9 versus 10.0 months, respectively, in patients aged ≥65-<75, ≥75, and ≥80 years. PFS analyses favored avelumab plus BSC versus BSC alone in all subgroups. No new safety concerns were identified in patients aged ≥65 years, including those treated for ≥12 months. Quality-adjusted time without symptoms or toxicity was 4.57 months longer with avelumab plus BSC versus BSC alone (a 30.35% relative improvement). Limitations include small sample size for the ≥80-year age subgroup and the exploratory design. CONCLUSIONS: These exploratory analyses support the efficacy and tolerability of avelumab 1L maintenance in patients aged ≥65 years with la/mUC that has not progressed following chemotherapy, suggesting that older age should not solely prevent a patient from receiving avelumab 1L maintenance.

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

Figure 3

Partitioned survival plots of TOX, TWiST, and REL for (A) avelumab plus BSC and (B) BSC alone based on Kaplan–Meier analysis in patients aged ≥65 years. In both plots, the OS curve (top curve) is partitioned by curves for PFS (middle curve) and TOX (bottom curve). The area between the curves illustrates the time in three health states: REL, TWiST, and TOX. BSC, best supportive care; OS, overall survival, PFS, progression-free survival.

A

OS, PFS, TOX

Figure 3 · Panel A

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel A 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 3:off origin start
查看结果
B

OS, PFS, TOX

Figure 3 · Panel B

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel B 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 3:off origin start
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1OS in subgroups defined by older age. (A) ≥65 years, (B) ≥65-<75 years, (C) ≥75 years, and (D) ≥80 years. BSC, best supportive care; CI, confidence interval; HR, hazard ratio; NE, not estimable; OS, overall survival.
非 KM Figure
Figure 2Investigator-assessed PFS in subgroups defined by older age. (A) ≥65 years, (B) ≥65-<75 years, (C) ≥75 years, and (D) ≥80 years. BSC, best supportive care; CI, confidence interval; HR, hazard ratio; PFS, progression-free survival.
非 KM Figure